



NDA 22-107

NDA APPROVAL

Novartis Pharmaceuticals Corporation
Attention: Kimberly D. Dickerson, Pharm.D.
One Health Plaza
East Hanover, NJ 07936-1080

Dear Dr. Dickerson:

Please refer to your March 19, 2007 new drug application (NDA) submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act for Tekturna HCT (aliskiren/hydrochlorothiazide) 150/12.5 mg, 150/25 mg, 300/12.5 mg, and 300/25 mg Tablets.

We also refer to your submissions dated March 27, April 27, May 2, 4, 11, 18, 30, July 19, September 17, 20, October 2, November 19, 29, 30 and December 7 (twice), 11 (twice), 12, and 20, 2007.

This new drug application provides for the use of Tekturna HCT (aliskiren/hydrochlorothiazide) 150/12.5 mg, 150/25 mg, 300/12.5 mg, and 300/25 mg Tablets for the treatment of hypertension.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical to the enclosed labeling (text for the package insert and text for the patient package insert). Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "SPL for approved NDA 22-107."

We note that your January 16, 2008 email submission includes agreed-upon labeling text for your package insert and patient package insert. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

We acknowledge your December 11, 2007 submission containing final printed carton and container labels.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application.

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see www.fda.gov/cder/ddmac.

If you issue a letter communicating important safety related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
HFD-001, Suite 5100
5515 Security Lane
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please contact Mr. John David, Regulatory Project Manager at (301) 796-1059.

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure: Agreed-upon labeling text

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Norman Stockbridge
1/18/2008 02:29:30 PM